Akebia Therapeutics (STU:AX9) LT-Debt-to-Total-Asset: 0.10 (As of Mar. 2026)

What is Akebia Therapeutics LT-Debt-to-Total-Asset?

Akebia Therapeutics STU:AX9 +0.94% 50 LT-Debt-to-Total-Asset is 0.10 as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 50/100 and a GF Value™ of €1.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Akebia Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.10.

Akebia Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.16) to Mar. 2026 (0.10). It may suggest that Akebia Therapeutics is progressively becoming less dependent on debt to grow their business.

Akebia Therapeutics (STU:AX9) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Akebia Therapeutics LT-Debt-to-Total-Asset Related Terms

Akebia Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics LT-Debt-to-Total-Asset Chart

Akebia Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.18

0.11

0.19

0.13

Akebia Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.14	0.13	0.13	0.10

50GF Score

Akebia Therapeutics Inc STU:AX9

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Akebia Therapeutics LT-Debt-to-Total-Asset Calculation

Akebia Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	41.205	/	321.587
	=	0.13

Akebia Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	31.482	/	313.58
	=	0.10

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.10 mean?

Akebia Therapeutics (STU:AX9) has a LT-Debt-to-Total-Asset of 0.10 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Akebia Therapeutics and its competitors.

Is Akebia Therapeutics' LT-Debt-to-Total-Asset too high?

Akebia Therapeutics' current LT-Debt-to-Total-Asset is 0.10. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Akebia Therapeutics' LT-Debt-to-Total-Asset compare to TKNO and ORGO?

Akebia Therapeutics' LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Akebia Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.15, compared to a current price of €0.98 — trading 14.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.10. Akebia Therapeutics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current LT-Debt-to-Total-Asset is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.98 is trading 14.4% below its estimated GF Value™ of €1.15. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AX9:

LT-Debt-to-Total-Asset: 0.10
GF Value™: €1.15 vs. price of €0.98 (14.4% below fair value)
GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TKNO ORGO SIGA ANIK LFCR ELTP DERM EBS ASRT NIKA XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges AKBA:USA

Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142

Website https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

50GF Score

Get the complete analysis for STU:AX9

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98

Price

€1.15

GF Value

View STU:AX9 Analysis

See LT-Debt-to-Total-Asset data for all stocks →